4 Web 2.0 Stocks Below Their IPO Price
Groupon's terrible rout Wednesday has investors worried that other Web 2.0 companies may be in dire straits.
All Work
Trey Thoelcke
4 S&P 500 Stocks That Could Be Up 50% by Year End
The following four S&P companies have a good shot at closing 2015 50% higher than their 52-week lows.
4 Non-Energy Stocks That Could Be Cut in Half by Year End
Here are four S&P 500 stocks that have nothing to do with oil prices that could be cut in half by the end of 2015.
Why Only a Fall in the Bond Market Can Stop a Fed Rate Hike in December
Only two things can stop a December rate hike now. One is war, and the other is a sharp rise in bond yields before the next Federal Open Market Committee (FOMC) meeting.
These Chinese Biotechs Are Severely Undervalued
Those who remember the bursting of the tech bubble at the turn of the millennium may have the nagging feeling that something vaguely similar, though on a smaller scale, just happened with biotech.
Why PulteGroup, DR Horton and Lennar Are Good Buys Now
Housing data have been a bit schizophrenic in recent months, but understanding the reason behind the confusion will reveal that home-building stocks are actually good buys right now.
Amazon Will Win Another Holiday Season Battle, but Will Wal-Mart Win the War?
Amazon may win another battle this holiday season, but at some point investors will remember that Wal-Mart makes a lot more money and pays its shareholders.
The 6 Most Shorted Nasdaq Stocks: Apple Still on the Rise
Between the September 30 and November 15 settlement dates, Apple displaced BlackBerry as it continued to climb the list of the most heavily shorted stocks traded on the Nasdaq.
The 6 Most Shorted NYSE Stocks: GE and Sprint Short Interest Surges
Among the most shorted stocks trading on the New York Stock Exchange, General Electric and Sprint drew the most attention from short sellers between the September 30 and November 15 settlement dates.
The Strongest Performing Biotech in 2015 Is a Surprise
ThinkstockBiotech is still in a rut for 2015, with stocks year to date being essentially unchanged. Since January 1, the Biotechnology Index is up only 0.3%, pretty much breakeven. While the first half of…
Big Oil to Outperform Amid Signs of a Bottom
Big Oil is now engaged in cost-cutting operations with mass layoffs and project cutbacks. This could start a positive feedback loop for both oil and oil stocks.
How the Technology of One Small Biotech Can Save Tetraphase
Tetraphase Pharmaceuticals continues to reel from the spectacular and unexpected failure of its flagship candidate, eravacycline.
Citigroup Earnings Will Reveal the Extent of Black Monday and Glencore Damage
Don’t expect Citigroup earnings to be pretty. There are three factors that could lead to an earnings miss.
The 6 Most Shorted NYSE Stocks: Sprint Short Interest Surges
After being cautious in the previous period, short sellers made their moves in the most shorted stocks trading on the New York Stock Exchange between the September 15 and September 30 settlement dates.
The 6 Most Shorted Nasdaq Stocks: Short Sellers Grow More Cautious
Between the September 15 and September 30 settlement dates, short interest in many of the most heavily shorted stocks traded on the Nasdaq dwindled somewhat.
Apple Short Interest Takes a Breather
Short interest in Apple retreated about 6% in the two-week reporting period ended September 30, the first drop since July.
Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze
Martin Shkreli has said he would lower the price of Daraprim back down but hasn’t actually done it. He probably figures that if he can outlast the initial wave of negative publicity, people will…
Why Chevron Will Outperform the Dow on the Way Back Up
Evidence suggests that the bottom could be in for the Dow, for now, and Chevron may be one of its best performers on the way back up.
5 Oversold Chinese Companies Worth a Look
Chinese stocks may have a while yet to fall before reaching bottom, but that doesn’t mean every single Chinese company is doomed to see much lower share prices from here.
Inside the Math of Axel Springer’s Business Insider Acquisition
For a site that was begging to be sold for $100 million as recently as two years ago, Business Insider did very well in achieving a price tag more than five times that amount.